Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probio-M9 with Radiotherapy and Immunotherapy in Advanced Digestive System Malignancies
NCT06349044Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
A Phase 2 trial of Lactobacillus rhamnosus M9 in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma, hepatocellular carcinoma (HCC), biliary tract carcinoma (BTC), colorectal adenocarcinoma, sponsored by Zhejiang Cancer Hospital. Started Mar 2024; status: recruiting.
02
Drugs
Lactobacillus rhamnosus M9
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomahepatocellular carcinoma (HCC)biliary tract carcinoma (BTC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT06349044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06349044.